Answers are grounded in this paper and cite their sources.
Background/Objectives: Quantify the economic burden of obesity in Italy and explore, through an illustrative scenario-based approach, the potential budgetary implications for the Italian National Health Service (NHS) of full reimbursement of modern Obesity Management Medications (OMMs), including GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists. Methods: Narrative review based on literature searches of PubMed/MEDLINE, Scopus, and Google Scholar from inception to September 2026 and covering the epidemiology and economic burden of obesity in Italy, the current AIFA reimbursement landscape, cost-effectiveness evidence for approved OMMs, and international reimbursement models. Evidence synthesized from cost-of-illness studies, clinical trials, health technology assessments, and economic modeling. Results: Obesity imposes an estimated €13 billion annual burden on Italy (direct costs €7.89 billion; indirect costs €5.45 billion). AIFA currently restricts reimbursement primarily to patients with obesity plus type 2 diabetes mellitus (T2DM) via Nota 13, excluding the majority of individuals with obesity. Modern pharmacotherapies, including semaglutide 2.4 mg and tirzepatide, achieve 12–22% weight reduction with favorable cost-effectiveness ratios in several non-Italian economic evaluations, whereas Italian-specific analyses are lacking. In an illustrative scenario-based estimate derived from indirect modelling assumptions (not a validated decision-analytic, budget-impact, or cost-effectiveness model, and without formal sensitivity analysis), full reimbursement could avoid approximately €2–4 billion in obesity-related healthcare costs over 10 years (gross avoided costs; medication expenditure was not netted off and net savings were not demonstrated) through prevention of T2DM, cardiovascular disease (CVD), obstructive sleep apnea (OSA), and other obesity-related comorbidities. Conclusions: Full reimbursement of evidence-based Obesity Management Medications (OMMs) may offer long-term value for the Italian NHS, although reimbursement decisions require dedicated Italian cost-effectiveness and budget-impact analyses. Policy priorities should include expanding AIFA Nota 13 criteria, implementing outcomes-based risk-sharing agreements, and formally recognizing obesity as a chronic disease in Italian health policy.
No takes yet. Share an insight, caveat, or question.
Vignera et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: